Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.

Marder SR, Hawes EM, Van Putten T, Hubbard JW, McKay G, Mintz J, May PR, Midha KK.

Psychopharmacology (Berl). 1986;88(4):480-3.

PMID:
3085136
2.

Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.

Marder SR, Midha KK, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J.

Br J Psychiatry. 1991 May;158:658-65.

PMID:
1860020
3.

Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.

Miller RS, Peterson GM, McLean S, Westhead TT, Gillies P.

J Clin Pharm Ther. 1995 Apr;20(2):55-62.

PMID:
7650075
4.

Clinical perspectives of some neuroleptics through development and application of their assays.

Midha KK, Marder SR, Jaworski TJ, McKay G, Hubbard JW, Hawes EM, Van Putten T, Wirshing WC, Aravagiri M.

Ther Drug Monit. 1993 Jun;15(3):179-89. Review.

PMID:
8101398
5.
6.

Costs and benefits of two doses of fluphenazine.

Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PR.

Arch Gen Psychiatry. 1984 Nov;41(11):1025-9.

PMID:
6437365
7.

Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.

Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR.

Arch Gen Psychiatry. 1987 Jun;44(6):518-21.

PMID:
3555385
8.

Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.

McKane JP, Robinson AD, Wiles DH, McCreadie RG, Stirling GS.

Br J Psychiatry. 1987 Sep;151:333-6.

PMID:
3322467
10.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

11.

Fluphenazine plasma levels and clinical response.

Marder SR, Van Putten T, Aravagiri M, Hawes EM, Hubbard JW, McKay G, Mintz J, Midha KK.

Psychopharmacol Bull. 1990;26(2):256-9.

PMID:
2236467
12.

Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.

Marder SR, Van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, Midha KK.

Psychopharmacol Bull. 1989;25(3):479-82.

PMID:
2626520
13.

Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Wiles DH, McCreadie RG, Whitehead A.

Psychopharmacology (Berl). 1990;101(2):274-81.

PMID:
2349370
14.
15.

Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia.

Chang SS, Javaid JI, Dysken MW, Casper RC, Janicak PG, Davis JM.

Psychopharmacology (Berl). 1985;87(1):55-8.

PMID:
3933037
16.
17.

Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.

Altamura AC, Curry SH, Montgomery S, Wiles DH.

Psychopharmacology (Berl). 1985;87(1):30-3.

PMID:
3933035
18.
20.
Items per page

Supplemental Content

Support Center